Clinical Comparison of Different Humidification Strategies During Noninvasive Ventilation With Helmet

January 23, 2019 updated by: Massimo Antonelli, Catholic University of the Sacred Heart

Background. Non invasive positive pressure ventilation (NIV) is among first line treatments of acute respiratory failure. Several interfaces are available for non-invasive ventilation.Despite full face and oronasal masks are more frequently used, some evidence suggests that helmets may optimize patients' comfort and NIV tolerability.

During NIV, humidification strategies (heat and moisture exchangers HME or heated humidifiers HH) may significantly affect patient's comfort and work of breathing.

Despite physiological data suggested heated humidification as the best strategy during NIV with full face masks, no differences were found in a randomized controlled study assessing the effects of HME or HH on a pragmatic clinical outcome.

However, the higher dead space (i.e. 18 L/min) and rebreathing rate observed during helmet NIV make such results not applicable to this particular setting.

The investigators designed a randomized-crossover trial to assess the effect of four humidification strategies during helmet NIV on patients with acute respiratory failure, in terms of comfort, work of breathing and patient-ventilator interaction.

Methods. All awake, collaborative, hypoxemic patients requiring mechanical ventilation will be considered for the enrollment. Hypercapnic patients (i.e.PaCO2>45 mmHg) will be excluded.

Each enrolled patient will undergo helmet NIV with all the following humidification strategies in a random order. Each period will last 60 minutes.

  • Passive humidification, double tube circuit.
  • Heated humification (MR 730, Fisher & Paykel, Auckland, New Zealand), humidification chamber temperature 33°C.
  • Heated humification (MR 730, Fisher & Paykel, Auckland, New Zealand), humidification chamber temperature 37°C.
  • Passive humidification with HME, Y-piece circuit.

Ventilatory settings (Draeger Evita xl or Evita infinity ventilators):

Pressure support ventilation; pressure support=20 cmH20; FiO2 titrated to obtain SpO2 between 92 and 98%; positive end-expiratory pressure=10 cmH2O; maximum inspiratory time 0.9 seconds; inspiratory flow trigger = 2 l/min; expiratory trigger: 30% of the maximum inspiratory flow; pressurization time=0,00 s.

Such settings will be kept unchanged during the whole study period. An oesophageal catheter will be placed and secured to measure oesophageal pressure (Pes) and gastric pressure (Pga) (Nutrivent, Italy): the reliability of the measured pressure will be confirmed with an airway occlusion test during NIV with oronasal mask. Work of breathing will be estimated with the pressure-time product (PTP) of the pleural pressure.

A pneumotachograph (KleisTek) will record flow, airway pressure, Pes and Pga on a dedicated laptop.

At the end of each cycle, the patient will be asked to rate his/her discomfort on a visual analog scale (VAS) modified for ICU patients. The level of dyspnea will be assessed with the Borg dyspnea scale.

The following parameters will be record at the end of each cycle:

Arterial pressure, heart rate, respiratory rate, SpO2, pH, PCO2, PaO2, SaO2. Airway and esophageal pressure signals will be reviewed offline to detect patient-ventilator asynchronies (ineffective efforts, double cycling, premature cycling, delayed cycling) and asynchrony index (number of asynchrony events divided by the total respiratory rate computed as the sum of the number of ventilator cycles (triggered or not) and of wasted efforts) will be computed. The trigger delay will be also measured. The pressurization and depressurization velocity will be assessed with the PTP airway index 300 and 500 (inspiratory and expiratory), as suggested by Ferrone and coworkers. The work of breathing (WOB) for each breath will be estimated by PTPes.

An hygrometer (Dimar SRL, Italy) will measure and record on a dedicated laptop Helmet temperature, relative and absolute humidity.

Primary endpoints: patient's comfort, work of breathing and asynchrony index.

Sample Sizing:

Given the physiological design of the study, the investigators did not make an a priori sample size and plan to enroll 24 patients.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Background Non invasive positive pressure ventilation (NIV) is among first line treatments of acute respiratory failure. In patients with new-onset respiratory failure, NIV was showed to reduce the rate of complications and the length of ICU stay, as compared to invasive mechanical ventilation[1] Several interfaces are available for non-invasive ventilation: full face masks, oronasal masks, nasal prongs and helmets[2].

Despite full face and oronasal masks are more frequently used, some evidence suggests that helmets may optimize patients' comfort and NIV tolerability. The helmet allows patients' interaction, speech, feeding and does not limit cough. In addition, skin necrosis, gastric distension, or eye irritation are seldom observed during helmet NIV, while may be consequences of long-term treatments with face masks. [3] On the contrary, helmet NIV hampers tidal volume monitoring, is contraindicated in hypercapnic patients and requires specific ventilator settings[4]. Lastly, when compared to face masks, helmets may increase the work of breathing and worsen patient-ventilator interaction[5][6][7].

During NIV, humidification strategies (heat and moisture exchangers HME or heated humidifiers HH) may significantly affect patient's comfort and work of breathing [8][9].

Despite physiological data suggested heated humidification as the best strategy during NIV with full face masks[8][9], no differences were found in a randomized controlled study assessing the effects of HME or HH on a pragmatic clinical outcome[10].

However, the higher dead space (i.e. 18 L/min) and rebreathing rate observed during helmet NIV make such results not applicable to this particular setting.

One only study assessed the effects of a HH during helmet low-flow continuous positive airway pressure on comfort in healthy volunteers[11]. Indeed, patients suffering from acute respiratory failure may behave differently, especially in terms of minute ventilation and maximum inspiratory flow.

A recent bench study identified a better patient-ventilator interaction when helmet NIV was provided through a double tube circuit, as compared to the Y-piece system [12]. The investigators designed a randomized-crossover trial to assess the effect of four humidification strategies during helmet NIV on patients with acute respiratory failure, in terms of comfort, work of breathing and patient-ventilator interaction.

Methods Design: monocentric, randomized, cross-over trial. Each enrolled patient will undergo helmet NIV with all the following humidification strategies in a random order. Each period will last 60 minutes.

  • Passive humidification, double tube circuit.
  • Heated humification (MR 730, Fisher & Paykel, Auckland, New Zealand), humidification chamber temperature 33°C.
  • Heated humification (MR 730, Fisher & Paykel, Auckland, New Zealand), humidification chamber temperature 37°C.
  • Passive humidification with HME, Y-piece circuit.

Ventilatory settings (Draeger Evita xl or Evita infinity ventilators):

Pressure support ventilation; pressure support=20 cmH20[4]; FiO2 titrated to obtain SpO2 between 92 and 98%; positive end-expiratory pressure=10 cmH2O[4]; maximum inspiratory time 0.9 seconds; inspiratory flow trigger = 2 l/min; expiratory trigger: 30% of the maximum inspiratory flow; pressurization time=0,00 s.

Such settings will be kept unchanged during the whole study period. An oesophageal catheter will be placed and secured to measure oesophageal pressure (Pes) and gastric pressure (Pga) (Nutrivent, Italy): the reliability of the measured pressure will be confirmed with an airway occlusion test during NIV with oronasal mask[13]. Work of breathing will be estimated with the pressure-time product (PTP) of the pleural pressure[13].

A pneumotachograph (KleisTek) will record flow, airway pressure, Pes and Pga on a dedicated laptop.

At the end of each cycle, the patient will be asked to rate his/her discomfort on a visual analog scale (VAS) modified for ICU patients. The level of dyspnea will be assessed with the Borg dyspnea scale[14].

The following parameters will be record at the end of each cycle:

Arterial pressure, heart rate, respiratory rate, SpO2, pH, PCO2, PaO2, SaO2. Airway and esophageal pressure signals will be reviewed offline to detect patient-ventilator asynchronies (ineffective efforts, double cycling, premature cycling, delayed cycling) and asynchrony index (number of asynchrony events divided by the total respiratory rate computed as the sum of the number of ventilator cycles (triggered or not) and of wasted efforts) will be computed[15]. The trigger delay will be also measured. The pressurization and depressurization velocity will be assessed with the PTP airway index 300 and 500 (inspiratory and expiratory), as suggested by Ferrone and coworkers[12]. The work of breathing (WOB) for each breath will be estimated by PTPes.

An hygrometer (Dimar SRL, Italy) will measure and record on a dedicated laptop Helmet temperature, relative and absolute humidity.

End point:

Primary endpoints: patient's comfort, work of breathing and asynchrony index.

Sample Sizing:

Given the physiological design of the study, the investigators did not make an a priori sample size and planned to enroll 24 patients.

Statistical analysis Qualitative data will be expressed as number of events (%) and continuous data as mean ± standard deviation or median [Interquartile range]. Comparisons concerning qualitative variables will be performed with the Mc-Namar test. Ordinal qualitative variables or non normal quantitative variables will be compared with the Friedman's Test, the wilcoxon sum of ranks test or the Mann-Whitney test, as appropriate. All analysis will be performed applying a bilateral hypothesis. P ≤ 0.05 will be considered significant. Statistical analysis will be performed with SPSS 20.0.

Study Type

Interventional

Enrollment (Actual)

20

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Rome, Italy, 00100
        • General ICU, A. Gemelli hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Awake and collaborative patients
  • Age>18 years
  • Need for noninvasive mechanical ventilation
  • Informed consent

Exclusion Criteria:

  • Cardiopulmonary resuscitation
  • Haemodynamic instability
  • Coma
  • Asma
  • Hypercapnia (paCO2>45 mmHg)
  • Recent gastric or abdominal surgery

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: HME
Passive humidification with heat and moisture exchanger, Y-piece circuit.
Measurements of respiratory mechanics and parameters, arterial blood gases and comfort
Experimental: HH33
Heated humification (MR 730, Fisher & Paykel, Auckland, New Zealand), humidification chamber temperature 33°C.
Measurements of respiratory mechanics and parameters, arterial blood gases and comfort
Experimental: HH37
Heated humification (MR 730, Fisher & Paykel, Auckland, New Zealand), humidification chamber temperature 33°C.
Measurements of respiratory mechanics and parameters, arterial blood gases and comfort
Experimental: NoH
Passive humidification, double tube circuit
Measurements of respiratory mechanics and parameters, arterial blood gases and comfort

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Comfort assessed by visual analogic scale modified for ICU patients
Time Frame: At the end of each 1-hour ventilation period
Patient's comfort, assessed by visual analogic scale modified for ICU patients
At the end of each 1-hour ventilation period
Patient-ventilator asynchrony. Asynchrony index
Time Frame: At the end of each 1-hour ventilation period
Asynchrony index number of asynchrony events divided by the total respiratory rate computed as the sum of the number of ventilator cycles (triggered or not) and of wasted efforts. Inspiratory trigger delay (time between the onset of patient's effort and ventilatory support). Pressurization and depressurization efficacy.
At the end of each 1-hour ventilation period
Work of breathing. Oesophageal pressure time product
Time Frame: At the end of each 1-hour ventilation period
Pressure time product of the esophageal pressure (PTPes) and pressure time product of the transdiaphragmatic pressure (PTPdi)
At the end of each 1-hour ventilation period

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
PaO2
Time Frame: At the end of each 1-hour ventilation period
At the end of each 1-hour ventilation period
respiratory rate
Time Frame: At the end of each 1-hour ventilation period
At the end of each 1-hour ventilation period
Dyspnea
Time Frame: At the end of each 1-hour ventilation period
Borg dyspnea score
At the end of each 1-hour ventilation period
Helmet humidity
Time Frame: At the end of each 1-hour ventilation period
At the end of each 1-hour ventilation period
Helmet temperature
Time Frame: At the end of each 1-hour ventilation period
At the end of each 1-hour ventilation period
PaCO2
Time Frame: At the end of each 1-hour ventilation period
At the end of each 1-hour ventilation period

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 1, 2017

Primary Completion (Actual)

January 23, 2019

Study Completion (Actual)

January 23, 2019

Study Registration Dates

First Submitted

July 27, 2015

First Submitted That Met QC Criteria

August 17, 2016

First Posted (Estimate)

August 23, 2016

Study Record Updates

Last Update Posted (Actual)

January 24, 2019

Last Update Submitted That Met QC Criteria

January 23, 2019

Last Verified

January 1, 2019

More Information

Terms related to this study

Other Study ID Numbers

  • 11491/15

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Undecided

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Respiratory Failure

Clinical Trials on Measurements

3
Subscribe